$98.39
0.01% day before yesterday
NYSE, Dec 27, 10:10 pm CET
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Novartis ADR Stock price

$98.39
-6.48 6.18% 1M
-8.16 7.66% 6M
-2.58 2.56% YTD
-1.32 1.32% 1Y
+15.45 18.63% 3Y
+8.11 8.98% 5Y
+9.54 10.73% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.01 0.01%
ISIN
US66987V1098
Symbol
NVS
Sector
Industry

Key metrics

Market capitalization $192.50b
Enterprise Value $210.76b
P/E (TTM) P/E ratio 11.40
EV/FCF (TTM) EV/FCF 14.28
EV/Sales (TTM) EV/Sales 4.34
P/S ratio (TTM) P/S ratio 3.96
P/B ratio (TTM) P/B ratio 4.54
Dividend yield 3.80%
Last dividend (FY24) $3.74
Revenue growth (TTM) Revenue growth -4.82%
Revenue (TTM) Revenue $48.59b
EBIT (operating result TTM) EBIT $14.40b
Free Cash Flow (TTM) Free Cash Flow $14.76b
Cash position $14.02b
EPS (TTM) EPS $8.63
P/E forward 17.51
P/S forward 3.82
EV/Sales forward 4.18
Short interest 0.22%
Show more

Is Novartis ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Novartis ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Novartis ADR forecast:

6x Buy
21%
19x Hold
68%
3x Sell
11%

Analyst Opinions

28 Analysts have issued a Novartis ADR forecast:

Buy
21%
Hold
68%
Sell
11%

Financial data from Novartis ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
48,587 48,587
5% 5%
100%
- Direct Costs 12,717 12,717
17% 17%
26%
35,870 35,870
0% 0%
74%
- Selling and Administrative Expenses 6,480 6,480
28% 28%
13%
- Research and Development Expense 8,966 8,966
3% 3%
18%
20,424 20,424
7% 7%
42%
- Depreciation and Amortization 6,029 6,029
32% 32%
12%
EBIT (Operating Income) EBIT 14,395 14,395
10% 10%
30%
Net Profit 17,603 17,603
125% 125%
36%

In millions USD.

Don't miss a Thing! We will send you all news about Novartis ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis ADR Stock News

Negative
Reuters
one day ago
A U.S. appeals court on Friday revived a whistleblower lawsuit accusing the Swiss drugmaker Novartis of paying illegal kickbacks to doctors to induce them to promote its blockbuster multiple sclerosis drug Gilenya.
Negative
Reuters
10 days ago
Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying 330 jobs would be affected.
Positive
Seeking Alpha
16 days ago
Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales guidance support our Buy rating. Key growth drivers include higher investments in R&D and strategic early stake acquisitions. The CEO's focus on cash generation, dividend growth, and share buybacks provides downside protection and supports EPS growth ahead of ...
More Novartis ADR News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 76,057
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today